85 results Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients. Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court. Aan de slag met de nieuwe Wet hergebruik van overheidsinformatie Op 18 juli 2015 is de Wet hergebruik van overheidsinformatie (de "Who") in werking getreden. Burgers en bedrijven kunnen bij publieketaakinstellingen een verzoek indienen tot het verstrekken van overheidsinformatie. Product counseling en intellectueel eigendom In deze podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten. Clémence Jonckheere Junior Associate Brussels Stibbe advises Agendia Stibbe advised Agendia on securing a $35 million investment from funds managed by Athyrium Capital Management. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of three healthcare residences for the elderly at Leiden, Oss and Amersfoort. The three residences are operated by ECR/Blueprint Group. Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million. Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland). Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company. Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands. Anya Murphy Junior Associate Brussels Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe. Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Pagination Previous page Page 2 Page 3 Current page 4 Page 5 Next page
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises leading pharmaceutical company Stibbe assisted a leading pharmaceutical company in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredients.
Stibbe advises Canon Advising Canon in connection with their dispute with the State of the Netherlands on the procurement of framework contracts. Case won up to and including the Supreme Court.
Aan de slag met de nieuwe Wet hergebruik van overheidsinformatie Op 18 juli 2015 is de Wet hergebruik van overheidsinformatie (de "Who") in werking getreden. Burgers en bedrijven kunnen bij publieketaakinstellingen een verzoek indienen tot het verstrekken van overheidsinformatie.
Product counseling en intellectueel eigendom In deze podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten.
Stibbe advises Agendia Stibbe advised Agendia on securing a $35 million investment from funds managed by Athyrium Capital Management.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of three healthcare residences for the elderly at Leiden, Oss and Amersfoort. The three residences are operated by ECR/Blueprint Group.
Stibbe advises Lundbeck Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.
Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland).
Stibbe advises SleepScore Labs Stibbe advised SleepScore Labs on the acquisition of Sleep.ai, a Netherlands-based digital health company.
Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands.
Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe.
Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.